Do we need more than one antidepressant for patients with major depressive disorder?

Expert Review of Neurotherapeutics

Volumn 11, Issue 11, 2011, Pages 1561-1564

  Pae, Chi Un ^a,b   Han, Changsu ^c   Jun, Tae Youn ^a  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Korea University College of Medicine   (South Korea)

Author keywords

antidepressant; combination; evidence; guideline; major depressive disorder; monotherapy

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ESCITALOPRAM; MIRTAZAPINE; PLACEBO; QUETIAPINE; VENLAFAXINE;

ADD ON THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 80054938952     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.150     Document Type: Article

References (26)

1. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am. J Psychiatry 157(4 Suppl.) 1-45 (2000)
2. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3(1), 5-43 (2002)
3. Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 22(4), 343-396 (2008)
4. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J Psychiatry 46(Suppl. 1), S38-S58 (2001)
5. Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J Psychiatry 168(7), 689-701 (2011)
6. Fleurence R, Williamson R, Jing Y et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol. Bull. 42(3), 57-90 (2009)
7. Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 14(3), 144-154 (2009)
8. Wisniewski SR, Rush AJ, Nierenberg AA et al. Can Phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am. J Psychiatry 166(5), 599-607 (2009)
9. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin. Psychopharmacol. 27(6), 672-676 (2007)
10. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 19(1), 34-40 (2009)
11. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 60(11), 1439-1445 (2009)
12. Rush AJ. Star D. Lessons learned and future implications. Depress. Anxiety 28(7), 521-524 (2011)
13. Thase ME. Antidepressant combinations: widely used, but far from empirically validated. Can. J Psychiatry 56(6), 317-323 (2011)
14. Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 19(7), 457-465 (2009)
15. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am. J Psychiatry 167(3), 281-288 (2010)
16. Papakostas GI, Worthington JJ 3rd, Iosifescu DV et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress. Anxiety 23(3), 178-181 (2006)
17. Leuchter AF, Lesser IM, Trivedi MH et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr. Pract. 14(5), 271-280 (2008)
18. Stewart JW, McGrath PJ, Deliyannides RA, Quitkin FM. Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? J. Psychiatr. Pract. 15(5), 337-345 (2009)
19. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry 51(2), 183-188 (2002)
20. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol. Psychiatry 55(3), 296-300 (2004)
21. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin. Psychiatry 60(5), 326-335 (1999)
22. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr. Scand. 108(1), 20-23 (2003)
23. Bobo WV, Chen H, Trivedi MH et al. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect. Disord. 133(3), 467-476 (2011)
24. Wiersma JE, Hovens JG, van Oppen P et al. The importance of childhood trauma and childhood life events for chronicity of depression in adults. J Clin. Psychiatry 70(7), 983-989 (2009)
25. Blasey CM, Debattista C, Roe R, Block T, Belanoff JK. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp. Clin. Trials 30(4), 284-288 (2009)
26. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am. J Psychiatry 166(1), 42-49 (2009)